Table 3.
Disproportionality signal analysis calculated by using the reporting odds ratio (ROR), comparing a monotherapeutical approach using each drug to all other PD-1/PD-L1/CTLA-4 agents, for 2017–2023. Slash (/): no ROR was calculated since no QT prolongation was reported in the database.
| Adverse Events | Pembrolizumab | Cemiplimab | Nivolumab | Atezolizumab | Avelumab | Durvalumab | Ipilimumab |
|---|---|---|---|---|---|---|---|
| Cardiac failure | 0.74 (0.63–0.87) |
2.05 (0.92–4.61) |
1.10 (0.97–1.26) |
0.65 (0.48–0.89) |
0.81 (0.42–1.56) |
0.74 (0.54–1.02) |
0.17 (0.07–0.40) |
| Atrial Fibrillation | 0.62 (0.51–0.75) |
0.44 (0.06–3.17) |
0.80 (0.68–0.95) |
0.86 (0.63–1.18) |
1.31 (0.72–2.38) |
0.52 (0.33–0.79) |
0.51 (0.28–0.92) |
| Myocardial infarction | 1.01 (0.81–1.26) |
1.52 (0.38–6.10) |
1.14 (0.94–1.38) |
1.18 (0.82–1.68) |
1.41 (0.67–2.97) |
1.40 (0.98–1.98) |
0.37 (0.15–0.89) |
| Pericardial disease | 1.13 (0.96–1.32) |
0.86 (0.21–3.44) |
1.14 (0.98–1.32) |
1.29 (1.00–1.66) |
0.45 (0.17–1.21) |
0.72 (0.50–1.04) |
0.17 (0.06–0.44) |
| Myocarditis | 1.01 (0.89–1.15) |
1.31 (0.54–3.16) |
0.85 (0.75–0.97) |
0.52 (0.38–0.70) |
0.97 (0.57–1.64) |
0.53 (0.38–0.74) |
0.53 (0.34–0.83) |
| QT prolongation | / | / | 0.31 (0.12–0.76) |
/ | / | / | 1.23 (0.3–5.02) |